The objective is to make most cancers a curable, chronic condition. But with soaring costs, crowded therapeutic competition, and new diagnostic reimbursement challenges ahead, can industry deliver?
How Digital Medicine Can Pinpoint Dosing Regimens to Optimize Drug Efficacy and Safety
Sponsored By Oracle
Multi-faceted Approaches to Meet Payer and Regulatory Evidence Requirements
Sponsored By UBC Express Scripts
Overcoming the Life Sciences Content Conundrum in a Multichannel World
Sponsored By Veeva